Delivery and healthcare: Amazon continues to invest in long-term opportunities

12/07/2018

Download

Alison Porter, Portfolio Manager on the Global Technology Team, discusses Amazon’s latest foray into the delivery and healthcare sectors and its implications for investors.

Amazon recently announced that it is accelerating a partly defensive move into logistics and offensive disruption of pharmacy and healthcare. These are examples of how Amazon is coming up with new ways to invest for long-term growth.

Delivery

Amazon is developing its long-term position as an ‘AWS for logistics’ with Amazon Delivery Service Partners. The concept of public cloud for information technology needs was introduced by Amazon via Amazon Web Services (AWS). In AWS, Amazon invested heavily in computer power and storage infrastructure, allowing other enterprises and new companies to rent capacity, hence lowering start-up costs and increasing flexibility.

With Amazon Delivery, entrepreneurs are invited to form small delivery companies of 20 to 40 vans – with up to 100 drivers – to help build more shipping capacity. Amazon will provide access to delivery technology and shipping capacity. This service differs from Amazon Flex where ‘delivery partners’ are paid an hourly rate to deliver Amazon parcels, working flexible hours via the app.

Amazon Delivery aims to enable not one individual but a small group of drivers to in effect form a small business startup, providing training, tax and payroll guidance, fuel discounts, vehicle leases and insurance. Amazon has said it will set minimum standards for pay.

It will be interesting to see how these startups evolve and if they are used exclusively for Amazon contract delivery. It is an evolution of Amazon’s existing delivery infrastructure and follows the company’s other ventures into leasing its own cargo planes and drones. This delivery capacity will be used for future growth of Amazon’s deliveries, while the company intends to maintain strong relationships for its existing deliveries with incumbent couriers such as UPS, United States Postal Service (USPS) and FedEx.

Image credit: iStock

Potential implications

  • Amazon is effectively lowering barriers to entry into the delivery business by using scale to lower prices on large expenses such as vehicles and insurance. This may have a long-term impact on companies that are building models around scale of delivery and logistics.
  • While Amazon Delivery may be expensive and raise costs in the near term, it has the potential to lower delivery costs in the long term. In the shorter term it could help ease cost negotiations with existing delivery providers (such as USPS).
  • Amazon should be able to capture and leverage data collected for miles driven and logistics capability/mapping.
  • The announcement is an example of how Amazon is also helping small and medium-sized enterprises (SMEs), challenging perceptions that the company is detrimental to small companies. Amazon has been criticised for degrading the high street. The scheme will also provide qualifying US military veterans with a $10,000 reimbursement to get started.

Healthcare

There has been long-term speculation over the extent of Amazon’s interest in healthcare. This interest piqued on the  announcement of the Berkshire Hathaway and JP Morgan joint venture on managed care in 2017 (See: Amazon’s customer focus and investing for long-term growth should pay off).

Image credit: iStock

A second recent Amazon announcement concerned the $1 billion purchase of PillPack, an online pharmacy that mails consumers prescriptions sorted by dosage. According to a ConsumerReports.org survey, 55% of Americans regularly take prescription medication. The market is worth around $400 billion in the US with around 80% of that market being particularly well suited for ecommerce given the prominence of recurring prescriptions for chronic illnesses. The PillPack acquisition gives Amazon a pharmacy license in every US state except Hawaii and Puerto Rico, as well as relationships with all the major pharmacy benefit managers (third-party administrator of prescription drug programmes for commercial health plans). Additionally, Amazon will gain valuable data on historical medication purchase patterns.

Unlike other areas of ecommerce, direct to home mail order prescriptions have actually fallen over the last decade with many early stage disruptors acquired by incumbent pharmacy benefit managers and retailers. Amazon’s entry is likely to spur a new era of disruption for pharmacy customer service delivery.

Potential implications

  • Amazon could use pharmacy delivery as an additional service offering for Amazon Prime – adding value to existing Prime members and addressing an older demographic that is less well penetrated. The average PillPack user used to be someone in their mid 40s but has crept up to the mid 50s over recent years.
  • The frequency of delivery/regularity for pharmacy requires logistics and distribution expertise and scale, which is another means for Amazon to leverage its developing logistics capability.
  • PillPack could also be incorporated into the Whole Foods (acquired in June 2017) retail structure, which currently does not have a pharmacy offering.

Short-term overreaction in healthcare, but long-term risks increased

The market’s initial reaction has been less positive to the full pharmacy food chain, with distributors, pharmacy benefit managers and prescription managers negatively assuming Amazon will fully move into all of these areas. On the Janus Henderson Global Technology Team we believe this to be a classic hype cycle overestimation in the short term but a significant threat in the long term. The opportunity on the consumer-facing side is large enough for Amazon to focus on direct to consumer for now.

Further moves into distribution or pharmacy benefit management (disintermediation) will be a long regulatory learning curve and may not be something Amazon can do organically,  whereas in food it can start with small steps followed by acquisitions later. Amazon will need ongoing cooperation from the rest of the healthcare supply chain to scale up in the short term.

Conclusion

Amazon’s further investments into delivery and healthcare represent more examples of technology disruption and innovation. As long-term investors, we are confident that these investments are building on Amazon’s long-term barriers to entry and its own technology ‘fly wheel’ that is increasing the company’s momentum and ability to take market share.

The increasing mix of high margin businesses in the Amazon portfolio (AWS and advertising) are facilitating investment in disruption at an accelerating rate. However, we are also mindful that these investments will bear higher costs in the short term, potentially dampening near-term profitability, while extending Amazon’s long-term growth trajectory.

These are the views of the author at the time of publication and may differ from the views of other individuals/teams at Janus Henderson Investors. Any securities, funds, sectors and indices mentioned within this article do not constitute or form part of any offer or solicitation to buy or sell them.

Past performance is not a guide to future performance. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.

The information in this article does not qualify as an investment recommendation.

For promotional purposes.


Important information

Please read the following important information regarding funds related to this article.

Janus Henderson Horizon Global Technology Fund

This document is intended solely for the use of professionals and is not for general public distribution.

The Janus Henderson Horizon Fund (the “Fund”) is a Luxembourg SICAV incorporated on 30 May 1985, managed by Henderson Management S.A. Any investment application will be made solely on the basis of the information contained in the Fund’s prospectus (including all relevant covering documents), which will contain investment restrictions. This document is intended as a summary only and potential investors must read the Fund’s prospectus and key investor information document before investing. A copy of the Fund’s prospectus and key investor information document can be obtained from Henderson Global Investors Limited in its capacity as Investment Manager and Distributor.

Issued in Europe by Janus Henderson Investors. Janus Henderson Investors is the name under which investment products and services are provided by Janus Capital International Limited (reg no. 3594615), Henderson Global Investors Limited (reg. no. 906355), Henderson Investment Funds Limited (reg. no. 2678531), AlphaGen Capital Limited (reg. no. 962757), Henderson Equity Partners Limited (reg. no.2606646), (each registered in England and Wales at 201 Bishopsgate, London EC2M 3AE and regulated by the Financial Conduct Authority) and Henderson Management S.A. (reg no. B22848 at 2 Rue de Bitbourg, L-1273, Luxembourg and regulated by the Commission de Surveillance du Secteur Financier). We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes.

Past performance is not a guide to future performance. The performance data does not take into account the commissions and costs incurred on the issue and redemption of units. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested. Tax assumptions and reliefs depend upon an investor’s particular circumstances and may change if those circumstances or the law change. If you invest through a third party provider you are advised to consult them directly as charges, performance and terms and conditions may differ materially.

Nothing in this document is intended to or should be construed as advice. This document is not a recommendation to sell or purchase any investment. It does not form part of any contract for the sale or purchase of any investment.

The Fund is a recognised collective investment scheme for the purpose of promotion into the United Kingdom. Potential investors in the United Kingdom are advised that all, or most, of the protections afforded by the United Kingdom regulatory system will not apply to an investment in the Fund and that compensation will not be available under the United Kingdom Financial Services Compensation Scheme.

Copies of the Fund’s prospectus and key investor information document are available in English, French, German, and Italian. Articles of incorporation, annual and semi-annual reports are available in English. Key Investor document is also available in Spanish. All of these documents can be obtained free of cost from the local offices of Janus Henderson Investors: 201 Bishopsgate, London, EC2M 3AE for UK, Swedish and Scandinavian investors; Via Dante 14, 20121 Milan, Italy, for Italian investors and Roemer Visscherstraat 43-45, 1054 EW Amsterdam, the Netherlands. for Dutch investors; and the Fund’s: Austrian Paying Agent Raiffeisen Bank International AG, Am Stadtpark 9, A-1030 Vienna; French Paying Agent BNP Paribas Securities Services, 3, rue d’Antin, F-75002 Paris; German Information Agent Marcard, Stein & Co, Ballindamm 36, 20095 Hamburg; Belgian Financial Service Provider CACEIS Belgium S.A., Avenue du Port 86 C b320, B-1000 Brussels; Spanish Representative Allfunds Bank S.A. Estafeta, 6 Complejo Plaza de la Fuente, La Moraleja, Alcobendas 28109 Madrid; Singapore Representative Janus Henderson Investors (Singapore) Limited, 138 Market Street, #34-03 / 04 CapitaGreen 048946; or Swiss Representative BNP Paribas Securities Services, Paris, succursale de Zurich, Selnaustrasse 16, 8002 Zurich who are also the Swiss Paying Agent. RBC Investor Services Trust Hong Kong Limited, a subsidiary of the joint venture UK holding company RBC Investor Services Limited, 51/F Central Plaza, 18 Harbour Road, Wanchai, Hong Kong, Tel: +852 2978 5656 is the Fund’s Representative in Hong Kong.

Information on this document is on Janus Henderson Investors’ best endeavours.

Specific risks

  • Shares can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
  • This fund is designed to be used only as one component in several in a diversified investment portfolio. Investors should consider carefully the proportion of their portfolio invested into this fund.
  • The Fund could lose money if a counterparty with which it trades becomes unwilling or unable to meet its obligations to the Fund.
  • If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
  • Changes in currency exchange rates may cause the value of your investment and any income from it to rise or fall.
  • If the Fund or a specific share class of the Fund seeks to reduce risks (such as exchange rate movements), the measures designed to do so may be ineffective, unavailable or detrimental.
  • The Fund's value may fall where it has concentrated exposure to a particular industry that is heavily affected by an adverse event.
  • Any security could become hard to value or to sell at a desired time and price, increasing the risk of investment losses.

Risk rating

Share

Important message